Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (1317)	7/6/2000 6:55:53 PM
From: nohalo	Respond to of 52153

Agree with you regarding general trend. I expect a divergence may occur sometime in the future, when Biotechs may rise at an accelerated pace because of the rapid and amazing pace of progress in many different areas of biotechnology, eg genomics, proteinomics, stem cell, gene chip technology, oncology etc. This may occur in tandem with some high tech weakness, probably first quarter 2001, when Fed actions will take hold, as either a resurgence of growth will compel the Fed to raise rates, or slow growth will hit tech earnings. All IMHO.